Discover 1,725 paid clinical trials in Detroit, Michigan. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,725
Active & Responsive
Study of EVO756 in Adults With Migraine
for
Migraine
Location: Farmington Hills MI, Ann Arbor MI, Canton OH,
Sponsor: Evommune, Inc.
Sex: All
Age: 18 - 64
Code: NCT07616128
Phase 2, Recruiting
Active & Responsive
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
for
Parkinson Disease
Location: Farmington Hills MI, Ann Arbor MI, Cleveland OH,
Sponsor: Appello Pharmaceuticals, Inc.
Sex: All
Age: 30 - 70+
Code: NCT07432958
Phase 2, Recruiting
Active & Responsive
A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults
for
Cervical Dystonia
Location: Farmington Hills MI, Chicago IL, New York NY,
Sponsor: Ipsen
Sex: All
Age: 18 - 70+
Code: NCT06937931
Phase 2, Recruiting
Active & Responsive
A Trial of CRD-4730 in HFrEF
for
Heart Failure With Reduced Ejection Fraction (HFrEF)
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
for
Autosomal Dominant Polycystic Kidney Disease
Location: Shelby MI, Ann Arbor MI, Chicago IL, Bethlehem PA,
Sponsor: Calico Life Sciences LLC
Sex: All
Age: 18 - 55
Code: NCT06902558
Phase 2, Recruiting
Active & Responsive
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Sex: All
Age: 55 - 70+
Code: NCT06585787
Phase 3, Recruiting
Active & Responsive
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention